ARMCX3

Across TCGA pan-cancer cohorts, ARMCX3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARMCX3 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARMCX3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARMCX3 expression acts as an unfavorable survival marker.

HNSC, OV, and CCRCC are the cancer types where ARMCX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.718	0.956	.010	21	view →
OV	DFS	Median	All	0.665	1.000	.014	12	view →
CCRCC	DFS	Quartile	III,IV	0.332	0.724	.021	12	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	7	view →
LSCC	DFS	Tertile	All	0.444	0.870	.024	3	view →
PDAC	OS	Tertile	III,IV	0.778	0.981	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARMCX3–HNSC (OS)

Open the HNSC breakdown →